GlassScriptPhysician profile
Ashley Jane Pounders
NPI 1457849929
$7,080.24
in general payments reported to CMS, 2019-2025
37 companies · $4,939 in 2025
The $4,939 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.25 · 2023: $132 · 2024: $1,992 · 2025: $4,939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,185 · Travel and Lodging: $2,424 · Consulting Fee: $1,300 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,185.17 |
| Travel and Lodging | $2,423.83 |
| Consulting Fee | $1,300.00 |
| Education | $154.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $3,974.94 | 2024-2025 | Datroway, Enhertu |
| Upsher-Smith Laboratories LLC | $383.48 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $377.95 | 2024-2025 | Imfinzi, Enhertu, Lynparza |
| Janssen Biotech, INC. | $334.20 | 2024-2025 | Darzalex, Tecvayli, Talvey |
| Merck Sharp & Dohme LLC | $246.51 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $246.30 | 2024-2025 | |
| Glaxosmithkline, LLC. | $149.05 | 2024-2025 | Zejula, Jemperli, Ojjaara |
| Eisai INC. | $145.68 | 2024-2025 | |
| Gilead Sciences, INC. | $112.03 | 2024-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $90.76 | 2024-2025 | Opdivo, Opdualag |
| Astellas Pharma US INC | $78.46 | 2025 | Vyloy |
| Taiho Oncology, INC. | $71.85 | 2024 | |
| Abbvie INC. | $68.25 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.20 | 2024 | Ninlaro, Iclusig |
| Adaptive Biotechnologies Corporation | $66.03 | 2024-2025 | Clonoseq |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $53.23 | 2025 | |
| Beone Medicines USA, INC. | $50.86 | 2025 | Brukinsa |
| Legend Biotech USA INC. | $49.83 | 2025 | Carvykti |
| Pfizer INC. | $47.63 | 2024-2025 | |
| Incyte Corporation | $45.77 | 2025 | Jakafi |
| Genentech USA, INC. | $43.36 | 2024-2025 | Venclexta |
| Sobi, INC | $32.93 | 2025 | |
| Tersera Therapeutics LLC | $31.54 | 2024-2025 | Zoladex |
| Geron Corporation | $29.84 | 2025 | Rytelo |
| Sumitomo Pharma America, INC. | $29.39 | 2025 | Orgovyx |
| Beigene USA, INC. | $28.64 | 2025 | Brukinsa |
| Pyros Pharmaceuticals, INC. | $26.25 | 2023 | Vigpoder |
| Genmab U.S., INC. | $24.92 | 2024 | Epkinly |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.23 | 2025 | |
| Azurity Pharmaceuticals, INC. | $22.00 | 2025 | Danziten |
| Lilly USA, LLC | $20.77 | 2024 | Jaypirca, Verzenio |
| Syndax Pharmaceuticals, INC. | $20.08 | 2025 | |
| Spectrum Pharmaceuticals INC. | $19.75 | 2025 | Rolvedon |
| Stemline Therapeutics INC. | $19.72 | 2025 | Orserdu |
| Exelixis INC. | $18.98 | 2024 | Cabometyx |
| Medtronic, INC. | $14.41 | 2023 | Truclear |
| Rigel Pharmaceuticals, INC. | $13.42 | 2024 | Tavalisse, Rezlidhia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Pounders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.